Advances in epilepsy

Current Opinion in Psychiatry

Volumn 12, Issue 5, 1999, Pages 549-553

  Besag, Frank M C ^a  

^a St Piers Lingfield   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CHOLINERGIC RECEPTOR; DIAZEPAM; ETIRACETAM; LAMOTRIGINE; MIDAZOLAM; PHENOBARBITAL; PHENYTOIN; PIRACETAM; TIAGABINE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADOLESCENT; ADULT; CHILD; DIARRHEA; DIPLOPIA; EPILEPSY; EPILEPTIC STATE; FOCAL EPILEPSY; HUMAN; INFANT; INFANTILE SPASM; LEARNING DISORDER; MEDICAL GENETICS; MYOCLONUS SEIZURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY POLYCYSTIC DISEASE; REVIEW; SIDE EFFECT; VERTIGO; VISUAL FIELD DEFECT;

EID: 0032697390     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-199909000-00004     Document Type: Review

References (41)

1. 1 Duncan JS. Imaging and epilepsy. Brain 1997; 120:339-377.
2. 2 Duncan JS, Fish DR. Integration of structural and functional data [editorial]. Curr Opin Neurol 1998; 11:119-122. A good discussion of the importance of integrating structural and functional data.
3. 3 Krakow K, Woermann FG, Symms MR, Allen PJ, Lemieux L, et al. EEG-triggered functional MRI of interictal epileptiform activity in patients with partial seizures. Brain (in press).
4. 4 Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997; 314:180-181.
5. 5 Harding GF. Severe persistent visual field constriction associated with vigabatrin. Benefit: risk ratio must be calculated for individual patients. BMJ 1998; 316:232-233.
6. 6 Sankar R, Wasterlain CG. Is the devil we know the lesser of two evils? Vigabatrin and visual fields. Neurology 1999; 52:1537-1538. An update on the controversy regarding the use of vigabatrin.
7. 7 Vanhatalo S, Paakkonen L. Visual field constriction in children treated with vigabatrin. Neurology 1999; 52:1713-1714. Limited but convincing data on visual field constriction in children.
8. 8 Appleton RE. The treatment of infantile spasms by paediatric neurologists in the UK and Ireland. Dev Med Child Neurol 1996; 38:278-279.
9. 9 Siemes H, Brandl U, Spohr HL, Volger S, Weschke B. Long-term follow-up study of vigabatrin in pretreated children with West syndrome. Seizure 1998; 7:293-297.
10. 10 Cossette P, Riviello JJ, Carmant L. ACTH versus vigabatrin in infantile spasms: a retrospective study. Neurology 1999; 52:1691-1694.
11. 11 Lhatoo SD, Sander JW. Infantile spasms and vigabatrin. Visual field defects may be permanent. BMJ 1999; 318:57.
12. 12 Kalviainen R, Brodie MJ, Duncan J, Chadwick D, Edwards D, Lyby K. A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures. Northern European Tiagabine Study Group. Epilepsy Res 1998; 30:31-40. Presents extensive data on the use of tiagabine.
13. 13 Beran RG, Currie J, Sandbach J, Plunkett M. Visual field restriction with new antiepileptic medication. Epilepsia 1998; 39 (Suppl 2):6.
14. 14 Kalviainen R, Nousiainen I, Mantyjarvi M, Riekkinen PP. Absence of concentric visual field defects in patients with long-term tiagabine monotherapy. Neurology 1999; 52 (suppl 2).
15. 15 Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res 1998; 29:147-154.
16. 16 Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 1998; 29:109-114.
17. 17 Kasteleijn-Nolst Trenite DG, Marescaux C, Stodieck S, Edelbroek PM, Oosting J. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res 1996; 25:225-230.
18. 18 Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 1998; 284:474-479.
19. 19 Klitgaard H, Matagne A, Gobert J, Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 1998; 353: 191-206.
20. 20 Besag FMC. Lamotrigine in the treatment of epilepsy in people with intellectual disability. J Intellect Disabil Res 1998; 42 (Suppl 1):50.
21. 21 Drug treatment of epilepsy in people with intellectual disability. J Intellect Disabil Res 1998; 42(suppl 1). An interesting collection of papers focusing on antiepileptic drug treatment of people with learning disability.
22. 22 Besag FMC, Berry DJ, Pool F, Newbery JE, Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998; 39:183-187.
23. 23 Pal DK, Das T, Chaudhury G, Johnson AL, Neville BG. Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet 1998; 351:19-23. An attempt to assess the real value of phenobarbital in the Third World: some questions are still left unanswered, however.
24. 24 de Silva M, MacArdle B, McGowan M, Hughes E, Stewart J, Neville BG, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347:709-713.
25. 25 Scott RC, Besag FMC, Neville BGR. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet 1999; 353:623-626. An attempt to find a better pre-hospital treatment of status epilepticus.
26. 26 Schachter SC, Saper CB. Vagus nerve stimulation. Epilepsia 1998; 39:677-686. A good review of the current situation with regard to vagal nerve stimulation.
27. 27 Ben-Menachem E. Modern management of epilepsy: vagus nerve stimulation. Baillières Clin Neurol 1996; 5:841-848.
28. 28 Parker AP, Polkey CE, Binnie CD, Madigan C, Ferrie CD, Robinson RO. Vagal nerve stimulation in epileptic encephalopathies. Pediatrics 1999; 103: 778-782. A valuable study of the role of vagal nerve stimulation in difficult-to-treat childhood epilepsies.
29. 29 Aicardi J. Vagal nerve stimulation in epileptic encephalopathies. Pediatrics 1999;103:821-822.
30. 30 Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329:1383-1388.
31. 31 Isojarvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllyla VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996; 39:579-584.
32. 32 Rattya J, Vainionpaa L, Knip M, Lanning P, Isojarvi JI. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999;103:588-593.
33. 33 Yerby MS, McCoy GB. Male infertility: possible association with valproate exposure. Epilepsia 1999; 40:520-521.
34. 34 Isojarvi JI, Rattya J, Myllyla VV, Knip M, Koivunen R, Pakarinen AJ, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43:446-451. Continues the debate on valproate and endocrine dysfunction.
35. 35 Bate L, Gardiner M. Genetics of inherited epilepsies. Epileptic Disorders 1999; 1:7-19. An excellent review of the subject.
36. 36 Berkovic SF, Mulley JC. The first gene for an idiopathic epilepsy: a fruitful collaboration of Australian clinical research and molecular genetics. Aust N Z J Med 1996; 26:154-156.
37. 37 Berkovic SF. Epilepsy genes and the genetics of epilepsy syndromes: the promise of new therapies based on genetic knowledge. Epilepsia 1997; 38 (Suppl 9):S32-S36.
38. 38 Berkovic SF, Scheffer IE. Genetics of human partial epilepsy. Curr Opin Neurol 1997; 10:110-114.
39. 39 Berkovic SF, Howell RA, Hay DA, Hopper JL. Epilepsies in twins: genetics of the major epilepsy syndromes. Ann Neurol 1998; 43:435-445.
40. 40 Phillips HA, Scheffer IE, Crossland KM, Bhatia KP, Fish DR, Marsden CD, et al. Autosomal dominant nocturnal frontal-lobe epilepsy: genetic heterogeneity and evidence for a second locus at 15q24. Am J Hum Genet 1998; 63:1108-1116.
41. 41 Kuzniecky RI, Barkovich AJ. Pathogenesis and pathology of focal malformations of cortical development and epilepsy. J Clin Neurophysiol 1996; 13:468-480.